transplantologiyaТрансплантологияTransplantologiya. The Russian Journal of Transplantation2074-05062542-0909IPO Association of Transplantologists10.23873/2074-0506-2026-18-1-80-90transplantologiya-1079Research ArticleКЛИНИЧЕСКИЕ НАБЛЮДЕНИЯCASE REPORTSЭффективность ванкомицина в лечении рефрактерного к стандартной и биологической терапии язвенного колита у реципиентов печениThe effectiveness of vancomycin in the treatment of ulcerative colitis refractory to standard and biological therapy in liver transplant recipientshttps://orcid.org/0009-0009-0242-5743СмирноваТ. О.SmirnovaT. O.

Татьяна Олеговна Смирнова, врач гастроэнтеролог отделения терапии/гастроэнтерологии

123098, Москва, ул. Маршала Новикова, д. 23

Tatiana O. Smirnova, Gastroenterologist of the Gastroenterology Department

23 Marshal Novikov St., Moscow 123098 

fedorovato@mail.ruhttps://orcid.org/0000-0001-8391-5211СюткинВ. Е.SyutkinV. E.

Владимир Евгеньевич Сюткин, д-р мед. наук, профессор кафедры хирургии с курсами онкохирургии, эндоскопии, хирургической патологии, клинической трансплантологии и органного донорства ИППО; ведущий научный сотрудник отделения трансплантации печени

123098, Москва, ул. Маршала Новикова, д. 23

129090, Москва, Большая Сухаревская пл., д. 3

Vladimir E. Syutkin, Dr. Sci. (Med.), Professor of the Surgery Department with the Courses of Oncology, Anesthesiology and Resuscitation, Endoscopy, Surgical Pathology, Clinical Transplantation and Organ Donation, the Medical and Biological University of Innovation and Continuing Education; Leading Researcher, Department for Liver Transplantation

23 Marshal Novikov St., Moscow 123098 

Bolshaya Sukharevskaya Sq., Moscow 129090

vladsyutkin@gmail.comhttps://orcid.org/0000-0003-2370-170XПариновО. В.ParinovO. V.

Олег Викторович Паринов, д-р мед. наук, заместитель генерального директора по медицинской части

123098, Москва, ул. Маршала Новикова, д. 23

Oleg V. Parinov, Dr. Sci. (Med.), Deputy General Medical Director

23 Marshal Novikov St., Moscow 123098 

oparinov@fmbcfmba.ruhttps://orcid.org/0000-0001-5691-5398ВосканянС. Э.VoskanyanS. E.

Сергей Эдуардович Восканян, чл.-корр. РАН, проф., д-р мед. наук, заместитель главного врача по хирургической помощи, руководитель центра хирургии и трансплантологии; заведующий кафедрой хирургии с курсами онкохирургии, эндоскопии, хирургической патологии, клинической трансплантологии и органного донорства ИППО

123098, Москва, ул. Маршала Новикова, д. 23

Sergey E. Voskanyan, Corresponding Member of the Russian Academy of Sciences, Prof., Dr. Sci. (Med.), Deputy Chief Physician for Surgical Care – Head of Surgery and Transplantation Center; Head of Department of Surgery with courses of Oncology, Endoscopy, Surgical Pathology, Clinical Transplantation and Organ Donation, Medical and Biological University of Innovations and Continuing Education

23 Marshal Novikov St., Moscow 123098 

voskanyan_se@mail.ruhttps://orcid.org/0009-0002-7068-747XКарпенковаВ. И.KarpenkovaV. I.

Валентина Ивановна Карпенкова, канд. мед. наук, заведующая отделением эндоскопии

123098, Москва, ул. Маршала Новикова, д. 23

Valentina I. Karpenkova, Cand. Sci. (Med.), Head of the Endoscopy Department

23 Marshal Novikov St., Moscow 123098 

varvara_karp@inbox.ruhttps://orcid.org/0009-0007-4831-0832СоловьеваЕ. А.SolovyovaE. A.

Елена Александровна Соловьева, заведующая отделением терапии/гастроэнтерологии

123098, Москва, ул. Маршала Новикова, д. 23

Elena A. Solovyova, Head of the Gastroenterology Department

23 Marshal Novikov St., Moscow 123098 

tim_elena_@mail.ruhttps://orcid.org/0000-0002-3171-6621РудаковВ. В.RudakovV. S.

Владимир Сергеевич Рудаков, канд. мед. наук, врач-хирург хирургического отделения по координации донорства органов и (или) тканей человека, врач-хирург хирургического отделения № 2

123098, Москва, ул. Маршала Новикова, д. 23

Vladimir S. Rudakov, Cand. Sci. (Med.), Surgeon, Surgical Department for the Coordination of Donation of Organs and (or) Human Tissues, Surgeon, Surgical Department No. 2

23 Marshal Novikov St., Moscow 123098 

rudakov_vc@list.ruФГБУ ГНЦ ФМБЦ им. А.И. Бурназяна ФМБА РоссииРоссияState Research Center – Burnasyan Federal Medical Biophysical Center of Federal Medical Biological AgencyRussian FederationФГБУ ГНЦ ФМБЦ им. А.И. Бурназяна ФМБА России; ГБУЗ «НИИ скорой помощи им. Н.В. Склифосовского ДЗМ»РоссияState Research Center – Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency; N.V. Sklifosovsky Research Institute for Emergency MedicineRussian Federation2026160320261818090Copyright © Смирнова Т.О., Сюткин В.Е., Паринов О.В., Восканян С.Э., Карпенкова В.И., Соловьева Е.А., Рудаков В.В., 20262026Смирнова Т.О., Сюткин В.Е., Паринов О.В., Восканян С.Э., Карпенкова В.И., Соловьева Е.А., Рудаков В.В.Smirnova T.O., Syutkin V.E., Parinov O.V., Voskanyan S.E., Karpenkova V.I., Solovyova E.A., Rudakov V.S.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.jtransplantologiya.ru/jour/article/view/1079Актуальность

Актуальность. Язвенный колит (ЯК) – хроническое воспалительное заболевание кишечника неизвестной этиологии. До 80% пациентов с первичным склерозирующим холангитом (ПСХ) имеют сопутствующие воспалительные заболевания кишечника. Трансплантация печени (ТП) является единственным радикальным способом лечения терминальных стадий хронических диффузных заболеваний печени. Лечение ЯК является сложной задачей, особенно у пациентов, перенесших трансплантацию печени и получающих иммуносупрессивную терапию. Микробиота играет важную роль в патогенезе ЯК, хотя данные об эффективности антибиотиков при лечении ЯК ограничены. Мы описываем эффект перорального приема ванкомицина у трех реципиентов печени с ЯК, рефрактерных к традиционной и биологической терапии.

Цель

Цель. Продемонстрировать эффективность перорального приема ванкомицина в лечении рефрактерного ЯК у реципиентов печени.

Материал и методы

Материал и методы. Представлены наблюдения за тремя реципиентами трансплантата печени с рефрактерным к стандартной и биологической терапии течением язвенного колита, получавших ванкомицин перорально 6 месяцев.

Результаты

Результаты. Достигнута ремиссия рефрактерного язвенного колита у реципиентов печени пероральным приемом ванкомицина.

Выводы

Выводы. Пероральный прием ванкомицина в ряде случаев может привести к клинической и эндоскопической ремиссии язвенного колита у реципиентов, у которых стандартная и биологическая терапия ЯК оказались не эффективны.

Background

Background. Ulcerative colitis (UC) is a chronic inflammatory bowel disease of unknown etiology. Up to 80% of patients with primary sclerosing cholangitis have concomitant inflammatory bowel disease. Liver transplantation is the only curative treatment for end-stage chronic diffuse liver diseases. Treatment of UC is challenging, especially in patients who underwent liver transplantation and receive immunosuppressive therapy. Microbiota plays an important role in the pathogenesis of UC, although data on the efficacy of antibiotics in the treatment of UC are limited. We describe the effect of oral vancomycin treatment in three liver transplant recipients with UC refractory to conventional and biological therapy. All three patients achieved clinical remission and mucosal healing with oral vancomycin orally. Oral vancomycin treatment was well tolerated and resulted in sustained clinical and endoscopic remission in all three patients.

Objective

Objective. To demonstrate the efficacy of oral vancomycin in the treatment of refractory ulcerative colitis in liver transplant recipients.

Material and methods

Material and methods. The article presents observations of three liver transplant recipients with ulcerative colitis refractory to standard and biological therapy, who received vancomycin orally for 6 months.

Results

Results. Remission of refractory ulcerative colitis in liver recipients was achieved by taking vancomycin orally.

Conclusion

Conclusion. Oral vancomycin administration in some cases lead to clinical and endoscopic remission of ulcerative colitis in recipients in whom standard and biological therapy for UC have not been effective.

ванкомицинтрансплантация печениязвенный колитvancomycinulcerative colitisliver transplantationReferences. Uko V, Thangada S, Radhakrishnan K. Liver disorders in inflammatory bowel disease. Gastroenterol Res Pract. 2012;2012:642923. PMID: 22474447 https://doi.org/10.1155/2012/642923. Uko V, Thangada S, Radhakrishnan K. Liver disorders in inflammatory bowel disease. Gastroenterol Res Pract. 2012;2012:642923. PMID: 22474447 https://doi.org/10.1155/2012/642923Kim YS, Hurley EH, Park Y, Ko S. Primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD): a condition exemplifying the crosstalk of the gut-liver axis. Exp Mol Med. 2023;55(7):1380–1387. PMID: 37464092 https://doi.org/10.1038/s12276-023-01042-9Kim YS, Hurley EH, Park Y, Ko S. Primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD): a condition exemplifying the crosstalk of the gut-liver axis. Exp Mol Med. 2023;55(7):1380–1387. PMID: 37464092 https://doi.org/10.1038/s12276-023-01042-9Singh S, Loftus EV Jr, Talwalkar JA. Inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Am J Gastroenterol. 2013;108(9):1417–1425. PMID: 23896954 https://doi.org/10.1038/ajg.2013.163Singh S, Loftus EV Jr, Talwalkar JA. Inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Am J Gastroenterol. 2013;108(9):1417–1425. PMID: 23896954 https://doi.org/10.1038/ajg.2013.163Mouchli MA, Singh S, Boardman L, Bruining DH, Lightner AL, Rosen CB, et al. Natural history of established and de novo inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Inflamm Bowel Dis. 2018;24(5):1074–1081. PMID: 29522202 https://doi.org/10.1093/ibd/izx096Mouchli MA, Singh S, Boardman L, Bruining DH, Lightner AL, Rosen CB, et al. Natural history of established and de novo inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Inflamm Bowel Dis. 2018;24(5):1074–1081. PMID: 29522202 https://doi.org/10.1093/ibd/izx096Ravikumar R, Tsochatzis E, Jose S, Allison M, Athale A, Creamer F, et al. Risk factors for recurrent primary sclerosing cholangitis after liver transplantation. J Hepatol. 2015;63(5):1139– 1146. PMID: 26186988 https://doi.org/10.1016/j.jhep.2015.07.005Ravikumar R, Tsochatzis E, Jose S, Allison M, Athale A, Creamer F, et al. Risk factors for recurrent primary sclerosing cholangitis after liver transplantation. J Hepatol. 2015;63(5):1139– 1146. PMID: 26186988 https://doi.org/10.1016/j.jhep.2015.07.005Visseren T, Erler NS, Heimbach JK, Eaton JE, Selzner N, Gulamhusein A, et al. Inflammatory conditions play a role in recurrence of PSC after liver transplantation: an international multicentre study. JHEP Rep. 2022;4(12):100599. PMID: 36426376 https://doi.org/10.1016/j.jhepr.2022.100599eCollection2022DecVisseren T, Erler NS, Heimbach JK, Eaton JE, Selzner N, Gulamhusein A, et al. Inflammatory conditions play a role in recurrence of PSC after liver transplantation: an international multicentre study. JHEP Rep. 2022;4(12):100599. PMID: 36426376 https://doi.org/10.1016/j.jhepr.2022.100599eCollection2022DecИвашкин В.Т., Шелыгин Ю.А., Абдулганиева Д.И., Абдулхаков Р.А., Алексеева О.А., Ачкасов С.И. и др. Рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России по диагностике и лечению взрослых больных язвенным колитом. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2015;25(1):48–65.Ivashkin VT, Shelygin YuA, Abdulganiyeva DI, Abdulkhakov RA, Alekseyeva OP, Achkasov SI, et al. Guidelines of the Russian gastroenterological association and Russian Association of Coloproctology on diagnostics and treatment of ulcerative colitis in adults. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2015;25(1):48–65. (In Russ.).European Association for the Study of the Liver. EASL Clinical Practice Guidelines on sclerosing cholangitis. J Hepatol. 2022;77(3):761–806. PMID: 35738507 https://doi.org/10.1016/j.jhep.2022.05.011European Association for the Study of the Liver. EASL Clinical Practice Guidelines on sclerosing cholangitis. J Hepatol. 2022;77(3):761–806. PMID: 35738507 https://doi.org/10.1016/j.jhep.2022.05.011Carbone M, Penna A, Mazzarelli C, De Martin E, Villard C, Bergquist A, et al. Liver Transplantation for Primary Sclerosing Cholangitis (PSC) with or without Inflammatory Bowel Disease (IBD)-A European Society of Organ Transplantation (ESOT) consensus statement. Transpl Int. 2023;36:11729. PMID: 37841645 https://doi.org/10.3389/ti.2023.11729eCollection2023.Carbone M, Penna A, Mazzarelli C, De Martin E, Villard C, Bergquist A, et al. Liver Transplantation for Primary Sclerosing Cholangitis (PSC) with or without Inflammatory Bowel Disease (IBD)-A European Society of Organ Transplantation (ESOT) consensus statement. Transpl Int. 2023;36:11729. PMID: 37841645 https://doi.org/10.3389/ti.2023.11729eCollection2023.Raine T, Bonovas S, Burisch J, Kucharzik T, Adamina M, Annese V, et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis. 2022;16(1):2–17. PMID: 34635919 https://doi.org/10.1093/eccojcc/jjab178Raine T, Bonovas S, Burisch J, Kucharzik T, Adamina M, Annese V, et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis. 2022;16(1):2–17. PMID: 34635919 https://doi.org/10.1093/eccojcc/jjab178Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019;114(3):384– 413. PMID: 30840605 https://doi.org/10.14309/ajg.0000000000000152Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019;114(3):384– 413. PMID: 30840605 https://doi.org/10.14309/ajg.0000000000000152Kannegieter NM, Hesselink DA, Dieterich M, Kraaijeveld R, Rowshani AT, Leenen PJ, et al. The Effect of tacrolimus and mycophenolic acid on CD14+ monocyte activation and function. PLoS One. 2017;12(1):e0170806. PMID: 28122021 https://doi.org/10.1371/journal.pone.0170806eCollection2017.Kannegieter NM, Hesselink DA, Dieterich M, Kraaijeveld R, Rowshani AT, Leenen PJ, et al. The Effect of tacrolimus and mycophenolic acid on CD14+ monocyte activation and function. PLoS One. 2017;12(1):e0170806. PMID: 28122021 https://doi.org/10.1371/journal.pone.0170806eCollection2017.Gómez-Massa E, Talayero P, Utrero-Rico A, Laguna-Goya R, Andrés A, Mancebo E, et al. Number and function of circulatory helper innate lymphoid cells are unaffected by immunosuppressive drugs used in solid organ recipients – a single centre cohort study. Transpl Int. 2020;33(4):402–413. PMID: 31908055 https://doi.org/10.1111/tri.13567Gómez-Massa E, Talayero P, Utrero-Rico A, Laguna-Goya R, Andrés A, Mancebo E, et al. Number and function of circulatory helper innate lymphoid cells are unaffected by immunosuppressive drugs used in solid organ recipients – a single centre cohort study. Transpl Int. 2020;33(4):402–413. PMID: 31908055 https://doi.org/10.1111/tri.13567Han JW, Joo DJ, Kim JH, Rha MS, Koh JY, Park HJ, et al. Early reduction of regulatory T cells is associated with acute rejection in liver transplantation under tacrolimus-based immunosuppression with basiliximab induction. Am J Transplant. 2020;20(8):2058–2069. PMID: 31965710 https://doi.org/10.1111/ajt.15789Han JW, Joo DJ, Kim JH, Rha MS, Koh JY, Park HJ, et al. Early reduction of regulatory T cells is associated with acute rejection in liver transplantation under tacrolimus-based immunosuppression with basiliximab induction. Am J Transplant. 2020;20(8):2058–2069. PMID: 31965710 https://doi.org/10.1111/ajt.15789Miroux C, Morales O, Ghazal K, Othman SB, de Launoit Y, Pancré V, et al. In vitro effects of cyclosporine A and tacrolimus on regulatory T-cell proliferation and function. Transplantation. 2012;94(2):123–131. PMID: 22743548 https://doi.org/10.1097/TP.0b013e3182590d8fMiroux C, Morales O, Ghazal K, Othman SB, de Launoit Y, Pancré V, et al. In vitro effects of cyclosporine A and tacrolimus on regulatory T-cell proliferation and function. Transplantation. 2012;94(2):123–131. PMID: 22743548 https://doi.org/10.1097/TP.0b013e3182590d8fGaro LP, Ajay AK, Fujiwara M, Beynon V, Kuhn C, Gabriely G, et al. Smad7 controls immunoregulatory PDL2/1-PD1 signaling in intestinal inflammation and autoimmunity. Cell Rep. 2019;28(13):3353–3366.e5. PMID: 31553906 https://doi.org/10.1016/j.celrep.2019.07.065Garo LP, Ajay AK, Fujiwara M, Beynon V, Kuhn C, Gabriely G, et al. Smad7 controls immunoregulatory PDL2/1-PD1 signaling in intestinal inflammation and autoimmunity. Cell Rep. 2019;28(13):3353–3366.e5. PMID: 31553906 https://doi.org/10.1016/j.celrep.2019.07.065Sannaa W, Almasry M, Peedikayil M, Grimshaw AA, Attamimi M, AlMutairdi A, et al. Effectiveness and safety of oral vancomycin for the treatment of inflammatory bowel disease associated with primary sclerosing cholangitis: a systematic review and pooled analysis. Therap Adv Gastroenterol. 20259;18:17562848241312766. PMID: 39802627 https://doi.org/10.1177/17562848241312766eCollection 2025.Sannaa W, Almasry M, Peedikayil M, Grimshaw AA, Attamimi M, AlMutairdi A, et al. Effectiveness and safety of oral vancomycin for the treatment of inflammatory bowel disease associated with primary sclerosing cholangitis: a systematic review and pooled analysis. Therap Adv Gastroenterol. 20259;18:17562848241312766. PMID: 39802627 https://doi.org/10.1177/17562848241312766eCollection 2025.Arbabzada N, Dennett L, Meng G, Peerani F. The effectiveness of oral vancomycin on inflammatory bowel disease in patients with primary sclerosing cholangitis: a systematic review. Inflamm Bowel Dis. 2025;31(7):2027–2035. PMID: 39495039 https://doi.org/10.1093/ibd/izae257Arbabzada N, Dennett L, Meng G, Peerani F. The effectiveness of oral vancomycin on inflammatory bowel disease in patients with primary sclerosing cholangitis: a systematic review. Inflamm Bowel Dis. 2025;31(7):2027–2035. PMID: 39495039 https://doi.org/10.1093/ibd/izae257Dickinson RJ, O'Connor HJ, Pinder I, Hamilton I, Johnston D, Axon AT. Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis. Gut. 1985;26(12):1380–1384. PMID: 3910524 https://doi.org/10.1136/gut.26.12.1380Dickinson RJ, O'Connor HJ, Pinder I, Hamilton I, Johnston D, Axon AT. Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis. Gut. 1985;26(12):1380–1384. PMID: 3910524 https://doi.org/10.1136/gut.26.12.1380Bianchimano P, Iwanowski K, Smith EM, Cantor A, Leone P, Bongers G, et al. Oral vancomycin treatment suppresses gut trypsin activity and preserves intestinal barrier function during EAE. iScience. 2023;26(11):108143. PMID: 37915599 https://doi.org/10.1016/j.isci.2023.108143eCollection2023Nov17.Bianchimano P, Iwanowski K, Smith EM, Cantor A, Leone P, Bongers G, et al. Oral vancomycin treatment suppresses gut trypsin activity and preserves intestinal barrier function during EAE. iScience. 2023;26(11):108143. PMID: 37915599 https://doi.org/10.1016/j.isci.2023.108143eCollection2023Nov17.Ayers, TD, Leonard-Puppa E, Kader HA, Waddell J, Watkins RD, Blanchard SS, et al. Oral vancomycin as an adjuvant treatment in IBD. Crohn's Colitis 360. 2019;1(2):otz015. https://doi.org/10.1093/crocol/otz015Ayers, TD, Leonard-Puppa E, Kader HA, Waddell J, Watkins RD, Blanchard SS, et al. Oral vancomycin as an adjuvant treatment in IBD. Crohn's Colitis 360. 2019;1(2):otz015. https://doi.org/10.1093/crocol/otz015Lev-Tzion R, Ledder O, Shteyer E, Tan MLN, Uhlig HH, Turner D. Oral vancomycin and gentamicin for treatment of very early onset inflammatory bowel disease. Digestion. 2017;95(4):310– 313. PMID: 28564649 https://doi.org/10.1159/000475660Lev-Tzion R, Ledder O, Shteyer E, Tan MLN, Uhlig HH, Turner D. Oral vancomycin and gentamicin for treatment of very early onset inflammatory bowel disease. Digestion. 2017;95(4):310– 313. PMID: 28564649 https://doi.org/10.1159/000475660Kasai K, Igarashi N, Tada Y, Kani K, Takano S, Yanagibashi T, et al. Impact of vancomycin treatment and gut microbiota on bile acid metabolism and the development of non-alcoholic steatohepatitis in mice. Int J Mol Sci. 2023;24(4):4050. PMID: 36835461 https://doi.org/10.3390/ijms24044050Kasai K, Igarashi N, Tada Y, Kani K, Takano S, Yanagibashi T, et al. Impact of vancomycin treatment and gut microbiota on bile acid metabolism and the development of non-alcoholic steatohepatitis in mice. Int J Mol Sci. 2023;24(4):4050. PMID: 36835461 https://doi.org/10.3390/ijms24044050Heumann D, Barras C, Severin A, Glauser MP, Tomasz A. Gram-positive cell walls stimulate synthesis of tumor necrosis factor alpha and interleukin-6 by human monocytes. Infect Immun. 1994;62(7):2715–2721. PMID: 7516310 https://doi.org/10.1128/iai.62.7.2715-2721.1994Heumann D, Barras C, Severin A, Glauser MP, Tomasz A. Gram-positive cell walls stimulate synthesis of tumor necrosis factor alpha and interleukin-6 by human monocytes. Infect Immun. 1994;62(7):2715–2721. PMID: 7516310 https://doi.org/10.1128/iai.62.7.2715-2721.1994

The authors declare that there are no conflicts of interest present.